Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Anirban P. Mitra, Vikram M. Narayan, Sharada Mokkapati, Tanner Miest, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, J. Erik Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne Schuckman, Tracy M. Downs, Robert S. Svatek, Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey L. Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O’Donnell, Richard Philipson, Seppo Ylä‐Herttuala, David G. Sawutz, Nigel Parker, David J. McConkey, Colin P. Dinney